These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23876043)

  • 21. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.
    Walker AK; Budac DP; Bisulco S; Lee AW; Smith RA; Beenders B; Kelley KW; Dantzer R
    Neuropsychopharmacology; 2013 Aug; 38(9):1609-16. PubMed ID: 23511700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
    Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical overview of NMDA-R antagonists and clinical practice.
    Davoudian PA; Wilkinson ST
    Adv Pharmacol; 2020; 89():103-129. PubMed ID: 32616204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain NMDA Receptors in Schizophrenia and Depression.
    Adell A
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32585886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
    Lally N; Nugent AC; Luckenbaugh DA; Ameli R; Roiser JP; Zarate CA
    Transl Psychiatry; 2014 Oct; 4(10):e469. PubMed ID: 25313512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
    Chaki S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnesium and ketamine in the treatment of depression.
    Górska N; Słupski J; Szałach ŁP; Włodarczyk A; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):549-553. PubMed ID: 31488789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NMDA receptor antagonists and pain: ketamine.
    Muir WW
    Vet Clin North Am Equine Pract; 2010 Dec; 26(3):565-78. PubMed ID: 21056300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of memantine.
    Johnson JW; Kotermanski SE
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism.
    Asim M; Wang B; Hao B; Wang X
    Neurochem Int; 2021 Jun; 146():105044. PubMed ID: 33862176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option.
    Hermens DF; Simcock G; Dutton M; Bouças AP; Can AT; Lilley C; Lagopoulos J
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109921. PubMed ID: 32169564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 38. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.
    Duman RS
    Dialogues Clin Neurosci; 2014 Mar; 16(1):11-27. PubMed ID: 24733968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
    Wilson C; Li S; Hannan AJ; Renoir T
    Neuropharmacology; 2020 May; 168():107998. PubMed ID: 32061666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dietary magnesium restriction reduces amygdala-hypothalamic GluN1 receptor complex levels in mice.
    Ghafari M; Whittle N; Miklósi AG; Kotlowski C; Schmuckermair C; Berger J; Bennett KL; Singewald N; Lubec G
    Brain Struct Funct; 2015 Jul; 220(4):2209-21. PubMed ID: 24807818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.